A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.

Citation

• Luke, J. J., Patel, M. R., Hamilton, E. P., Chmielowski, B., Ulahannan, S. V., Kindler, H. L., . . . Blumenschein, G. (2020). A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.. Journal of Clinical Oncology, 38(15_suppl), 3004. doi:10.1200/jco.2020.38.15_suppl.3004

Digital Object Identifier (doi)

• 10.1200/jco.2020.38.15_suppl.3004

Web Of Science Accession Number

Start Page

• 3004

End Page

• 3004

Volume

• 38

Issue

• 15_suppl

Place Of Publication

Abstract

UOW Authors

•   Clingan, Phillip (external author)

Publication Date

• 2020

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Luke, J. J., Patel, M. R., Hamilton, E. P., Chmielowski, B., Ulahannan, S. V., Kindler, H. L., . . . Blumenschein, G. (2020). A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.. Journal of Clinical Oncology, 38(15_suppl), 3004. doi:10.1200/jco.2020.38.15_suppl.3004

Digital Object Identifier (doi)

• 10.1200/jco.2020.38.15_suppl.3004

Web Of Science Accession Number

Start Page

• 3004

End Page

• 3004

Volume

• 38

Issue

• 15_suppl

Place Of Publication